iBio, Inc. SEC filings IBIO
iBio, Inc. has 909 filings in SEC EDGAR's recent list, going back to Mar 7, 2008. Its latest annual report, Form ARS, was filed on Sep 4, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 12, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (officer or director change, bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Sep 4, 2026 | Sep 4, 2026 |
| PRE 14A | Preliminary proxy statement | Aug 20, 2026 | Oct 14, 2026 |
| DEF 14A | Proxy statement | Oct 6, 2025 | Nov 20, 2025 |
| DEF 14A | Proxy statement | Oct 10, 2024 | Oct 10, 2024 |
| DEF 14A | Proxy statement | Oct 26, 2023 | Nov 27, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2023 | Nov 27, 2023 |
| DEFA14A | Additional proxy material | Dec 2, 2022 | — |
| DEF 14A | Proxy statement | Oct 26, 2022 | Dec 8, 2022 |
| DEFA14A | Additional proxy material | May 26, 2022 | — |
| DEF 14A | Proxy statement | May 24, 2022 | Jun 30, 2022 |
| DEFA14A | Additional proxy material | May 13, 2022 | — |
| DEFA14A | Additional proxy material | May 13, 2022 | — |
| PRE 14A | Preliminary proxy statement | May 12, 2022 | Jun 30, 2022 |
| DEFA14A | Additional proxy material | Dec 22, 2021 | — |
| DEFA14A | Additional proxy material | Dec 21, 2021 | — |
| DEFA14A | Additional proxy material | Dec 10, 2021 | — |
| DEFA14A | Additional proxy material | Dec 3, 2021 | — |
| DEFA14A | Additional proxy material | Nov 30, 2021 | — |
| DEFA14A | Additional proxy material | Nov 30, 2021 | — |
| DEFA14A | Additional proxy material | Nov 30, 2021 | — |
| DEFA14A | Additional proxy material | Nov 24, 2021 | — |
| DEFA14A | Additional proxy material | Nov 17, 2021 | — |
| DEFA14A | Additional proxy material | Nov 16, 2021 | — |
| DEFA14A | Additional proxy material | Nov 9, 2021 | — |
| DEFA14A | Additional proxy material | Nov 9, 2021 | — |
| DEFA14A | Additional proxy material | Oct 26, 2021 | — |
| DEFA14A | Additional proxy material | Oct 26, 2021 | — |
| DEF 14A | Proxy statement | Oct 26, 2021 | Dec 9, 2021 |
| PRE 14A | Preliminary proxy statement | Oct 13, 2021 | Dec 9, 2021 |
| DEFA14A | Additional proxy material | Nov 6, 2020 | — |
| DEF 14A | Proxy statement | Nov 3, 2020 | Dec 9, 2020 |
| PRE 14A | Preliminary proxy statement | Oct 23, 2020 | Dec 9, 2020 |
| DEFA14A | Additional proxy material | Mar 2, 2020 | — |
| DEFA14A | Additional proxy material | Feb 6, 2020 | — |
| DEF 14A | Proxy statement | Jan 23, 2020 | Feb 10, 2020 |
| PRE 14A | Preliminary proxy statement | Jan 13, 2020 | Feb 10, 2020 |
| DEFA14A | Additional proxy material | Jan 9, 2020 | — |
| DEF 14A | Proxy statement | Nov 19, 2018 | Dec 18, 2018 |
| PRE 14A | Preliminary proxy statement | Nov 9, 2018 | Dec 18, 2018 |
| DEF 14A | Proxy statement | Apr 3, 2018 | Apr 23, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 21, 2018 | Apr 23, 2018 |
| DEFA14A | Additional proxy material | Dec 7, 2017 | — |
| DEF 14A | Proxy statement | Nov 27, 2017 | Dec 19, 2017 |
| PRE 14A | Preliminary proxy statement | Nov 15, 2017 | Nov 15, 2017 |
| DEF 14A | Proxy statement | Apr 6, 2017 | May 4, 2017 |
| DEF 14A | Proxy statement | Mar 11, 2016 | Apr 7, 2016 |
| DEFA14A | Additional proxy material | Mar 2, 2016 | — |
| PRE 14A | Preliminary proxy statement | Feb 29, 2016 | Feb 29, 2016 |
| DEFA14A | Additional proxy material | Jan 29, 2016 | — |
| DEFA14A | Additional proxy material | Jan 14, 2016 | — |
| DEF 14A | Proxy statement | Nov 12, 2014 | Dec 10, 2014 |
| DEF 14A | Proxy statement | Nov 18, 2013 | Dec 17, 2013 |
| PRE 14A | Preliminary proxy statement | Nov 5, 2013 | Nov 5, 2013 |
| DEF 14A | Proxy statement | Nov 16, 2012 | Dec 18, 2012 |
| DEF 14A | Proxy statement | Nov 8, 2011 | Dec 8, 2011 |
| DEF 14A | Proxy statement | Nov 10, 2010 | Dec 9, 2010 |
| PRE 14A | Preliminary proxy statement | Oct 28, 2010 | Dec 8, 2010 |
| DEF 14A | Proxy statement | Oct 28, 2009 | Dec 16, 2009 |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBIO (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420720
- Former names
- iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.